Ceapro Defends Claim from AVAC Ltd.

Ceapro Defends Claim from AVAC Ltd.

ID: 65380

(firmenpresse) - EDMONTON, ALBERTA -- (Marketwire) -- 09/13/11 -- Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the Company") announced today it and its wholly owned subsidiary, Ceapro Veterinary Products Inc., were served with a Statement of Claim filed in the Court of Queens Bench of Alberta by AVAC Ltd. ("AVAC"). Pursuant to the Statement of Claim, AVAC alleges damages of $724,500. The amounts claimed relate to a royalty agreement that was entered into in 2005 (the "2005 Agreement"). Pursuant to the 2005 Agreement, AVAC provided project funding of $362,250 for product innovation development in the area of veterinary therapeutics and active ingredients (the "Project") and obligated Ceapro to pay a royalty calculated with reference to sales generated from products developed out of the Project. Ceapro has complied with all obligations required of it pursuant to the 2005 agreement including making all required royalty payments.

Consequently, Ceapro will be filing a Statement of Defence which denies all allegations contained in the Statement of Claim and will be taking all other steps required of it to vigorously defend AVAC's allegations.

About Ceapro Inc.

Ceapro Inc. is a Canadian growth-stage biotechnology company. Primary business activities relate to the development and commercialization of active ingredients for personal care and cosmetic industries using proprietary technology and natural, renewable resources. To learn more about Ceapro, visit .

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.



Contacts:
Ceapro Inc.
Branko Jankovic
Chief Financial Officer
(Edmonton): (780) 917-8376



Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  Thallion Provides Update on Phase II SHIGATEC Trial Easton Pharmaceuticals to Enter Into Clinical Safety Trials of VIORRA for North American Market
Bereitgestellt von Benutzer: MARKET WIRE
Datum: 13.09.2011 - 13:00 Uhr
Sprache: Deutsch
News-ID 65380
Anzahl Zeichen: 1032

contact information:
Town:

EDMONTON, ALBERTA



Kategorie:

Biotech



Diese Pressemitteilung wurde bisher 236 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Ceapro Defends Claim from AVAC Ltd."
steht unter der journalistisch-redaktionellen Verantwortung von

Ceapro Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Ceapro Inc.



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z